99mTc-labeling and in vitro and in vivo evaluation of HYNIC- and (Nalpha-His)acetic acid-modified [D-Glu1]-minigastrin.
Gastrin/CCK-2 receptors are overexpressed in a number of tumors such as medullary thyroid cancer (MTC) and small cell lung cancer (SCLC). Recently [D-Glu1]-minigastrin (MG) has been radiolabeled with 131I, 111In, and 90Y and evaluated in patients. This study describes the labeling and evaluation of MG with technetium-99m using two different labeling approaches: HYNIC as bifunctional coupling agent and (Nalpha-His)Ac as tridentate ligand for 99mTc(CO3) labeling. Labeling was perfomed at high specific activities using Tricine and EDDA as coligands for HYNIC-MG and [99mTc(OH2)3(CO)3]+ for (Nalpha-His)Ac-MG. Stability experiments were carried out by reversed phase HPLC analysis in PBS, serum, histidine, and cysteine solutions, as well as rat liver and kidney homogenates. Receptor binding and internalization experiments were performed using CCK-2 receptor positive AR42J rat pancreatic tumor cells. Biodistribution experiments were carried out in nude mice carrying AR42J tumors by injection of 99mTc-labeled peptide with or without coinjection of 50 microg of minigastrin I human (MGh). HYNIC-MG and (Nalpha-His)Ac-MG could be radiolabeled at high specific activities (>1 Ci/micromol). For HYNIC-MG, high labeling yields (>95%) were achieved using Tricine and EDDA as coligands. Stability experiments of all 99mTc-labeled conjugates revealed a high stability of the label in PBS and serum as well as toward challenge with histidine and cysteine. Incubation in kidney homogenates resulted in a rapid degradation of all conjugates with <10% intact peptide after 60 min at 37 degrees C, with no considerable differences between the radiolabeled conjugates; a somewhat lower degradation rate was seen in liver homogenates. Protein binding varied considerably with lowest levels for 99mTc-EDDA/HYNIC-MG. Competition experiments of unlabeled conjugates on AR42J membranes versus [125I-Tyr12]-gastrin I showed high CCK-2 receptor affinity for all conjugates under study. Internalization behavior was very rapid for all radiolabeled conjugates in the order of 99mTc-(Nalpha-His)Ac-MG > 99mTc-EDDA/HYNIC-MG > 99mTc-Tricine/HYNIC-MG. In tumor-bearing nude mice the highest tumor-uptake was observed with 99mTc-EDDA/HYNIC-MG (8.1%ID/g) followed by 99mTc-Tricine/HYNIC-MG (2.2%ID/g) and 99mTc-(Nalpha-His)Ac-MG (1.2%ID/g) which correlated with kidney uptake (101.0%ID/g, 53.8%ID/g, 1.8%ID/g respectively). In this series of compounds 99mTc-EDDA/HYNIC-MG with its very high tumor/organ ratios except for kidneys seems to be the most promising agent to target CCK-2 receptors. Despite promising properties concerning receptor binding, internalization, and in vitro stability, 99mTc-(Nalpha-His)Ac-MG showed low tumor uptake in vivo.
von Guggenberg
E
E
Department of Nuclear Medicine, Leopold-Franzens-University of Innsbruck, Austria.
Behe
M
M
Behr
T M
TM
Saurer
M
M
Seppi
T
T
Decristoforo
C
C
D000085:Acetates / Q000737:chemistry*; D000818:Animals; D001692:Biological Transport; D045744:Cell Line, Tumor; D002851:Chromatography, High Pressure Liquid; D005755:Gastrins / Q000737:chemistry* / Q000378:metabolism / Q000493:pharmacokinetics; D005977:Glutarates / Q000737:chemistry*; D006639:Histidine / Q000737:chemistry*; D006801:Humans; D006834:Hydrazines / Q000737:chemistry*; D051379:Mice; D015394:Molecular Structure; D009539:Nicotinic Acids / Q000737:chemistry*; D010190:Pancreatic Neoplasms / Q000175:diagnosis / Q000378:metabolism; D011485:Protein Binding; D051381:Rats; D043887:Receptor, Cholecystokinin B / Q000032:analysis* / Q000378:metabolism; D013194:Staining and Labeling; D017556:Technetium Compounds / Q000737:chemistry*; D014018:Tissue Distribution
C120392:6-hydrazinopyridine-3-carboxylic acid; D000085:Acetates; D005755:Gastrins; D005977:Glutarates; D006834:Hydrazines; D009539:Nicotinic Acids; D043887:Receptor, Cholecystokinin B; D017556:Technetium Compounds; C010971:glutaconic acid; C008530:minigastrin; D006639:Histidine